erlotinib has been researched along with Breast Cancer in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Qian, Y; Xu, C; Zhang, H; Zhang, HJ; Zhao, J; Zhu, HL | 1 |
| Fokin, VV; Jo, M; Koizumi, K; Prangsaengtong, O; Priprem, A; Sanphanya, K; Shibahara, N; Vajragupta, O; Wattanapitayakul, SK | 1 |
| Abd El-Karim, SS; Ahmed, NS; Anwar, MM; El-Hallouty, SM; Srour, AM | 1 |
| Arya, GC; Jaitak, V; Kaur, K | 1 |
| Abd El-Meguid, EA; Awad, HM; El Kerdawy, AM; Moustafa, GO; Naglah, AM | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
3 review(s) available for erlotinib and Breast Cancer
| Article | Year |
|---|---|
Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; Female; Humans; Isoxazoles | 2021 |
Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Topics: Antineoplastic Agents; Benzothiazoles; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Humans; Liver Neoplasms; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Vascular Endothelial Growth Factor Receptor-2 | 2022 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
3 other study(ies) available for erlotinib and Breast Cancer
| Article | Year |
|---|---|
Synthesis, molecular modeling, and biological evaluation of cinnamic acid metronidazole ester derivatives as novel anticancer agents.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Cinnamates; Crystallography, X-Ray; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Humans; Metronidazole; Models, Molecular; Receptor, ErbB-2 | 2010 |
Synthesis and evaluation of 1-(substituted)-3-prop-2-ynylureas as antiangiogenic agents.
Topics: Angiogenesis Inhibitors; Binding Sites; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Female; HeLa Cells; Humans; Inhibitory Concentration 50; Models, Molecular; Urea | 2012 |
Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Breast Neoplasms; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; MCF-7 Cells; Molecular Docking Simulation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Thiazoles | 2020 |